Advancing Respiratory Infection Research Through Real-World Evidence

Viral respiratory infections – including LRTD, RSV, COVID-19, and influenza – present complex clinical, treatment, and prevention challenges requiring deep real-world intelligence.

Due to changing treatment options, evolving vaccination strategies and changing variants of these viruses, robust evidence capturing authentic patient experiences and clinical practice patterns is essential. This evidence can help in informing treatment strategies, optimizing prevention approaches including vaccination uptake, supporting rapid response protocols, and engaging clinician and patient communities.

Adelphi Real World’s Disease Specific Programmes (DSPs) in Infectious Diseases are designed to meet these evidence demands for respiratory viral infections. Additionally, we have a secondary data team with expertise in infectious diseases.

Unlocking Respiratory Viral Infection Intelligence

Our Infectious Disease DSPs engage relevant, specialist clinicians and affected patients to generate actionable evidence grounded in real-world practice:

Disease Recognition & Clinical Management

Understand how specialists diagnose, assess severity, and manage LRTD, RSV, COVID-19, and influenza – capturing diagnostic approaches, disease severity stratification, hospitalization decision-making, and treatment initiation protocols in routine clinical settings.

Treatment Pathways & Therapeutic Strategies

Benchmark real-world therapy selection: how clinicians choose, initiate, and optimize antiviral treatments, monoclonal antibodies, immunomodulatory agents, and supportive care – from outpatient management through intensive care – including treatment timing and sequencing.

Prevention & Risk Mitigation

Explore prevention strategies and risk assessment approaches: how specialists implement and optimize preventive interventions, including vaccination uptake and coverage, high-risk population identification, seasonal preparedness, variant tracking, and transmission prevention patterns across patient populations.

Clinical Outcomes & Disease Control

Understanding real-world effectiveness: symptom resolution, hospitalization rates, ICU admission patterns, mechanical ventilation use, recovery timelines, post-acute complications, and functional restoration across diverse patient populations and healthcare systems.

Patient Perspective & Lived Experience

Capture the patient voice: symptom severity and duration, treatment tolerability, side effect burden, impact on work and daily activities, healthcare access challenges, vaccination acceptance, and psychosocial wellbeing.

Treatment Gaps & Emerging Needs

Identify areas where current management is inadequate, vaccine effectiveness in real-world settings, equitable access barriers, treatment delays, and opportunities for therapeutic innovation and outbreak preparedness from both the patient and physician perspective.

Respiratory Infections Disease Specific Programmes (DSP) Portfolio

Respiratory Infection Disease Specific Programmes (DSP) Portfolio

Why Partner With Adelphi?

Respiratory Infection Expertise

Deep specialization across LRTD, RSV, COVID-19, and influenza diagnosis, treatment, and prevention strategies.

Specialist Clinician Networks

Access to emergency medicine physicians, infectious disease practitioners, respiratory specialists, and critical care experts across diverse care settings.

Comprehensive Condition Coverage

Evidence spanning RSV management, COVID-19 treatment and vaccination, and seasonal influenza care, as well as management of patients with LRTD.

Patient-Informed Intelligence

Evidence grounded in real patient experiences, including symptom impact, vaccination decisions, treatment efficacy, and recovery experiences.

Rigorous Methodology

Robust data collection capturing clinical outcomes, treatment patterns, and patient-reported experiences during acute infection episodes.

Strategic Intelligence

Intelligence supporting clinical development, vaccination strategies, public health response planning, outbreak preparedness, and healthcare system readiness.

Secondary Data Capabilities

115 secondary RWD studies since 2014, covering 50+ disease areas and 35+ data sources globally
Studies across multiple evidence archetypes, including classification algorithms, comparative effectiveness, treatment patterns, HCRU, economic modelling, and safety
30+ RWD landscaping and feasibility projects since 2017, across 80+ geographies and 25+ disease areas, covering 2000+ real world data sources worldwide
Patient, caregiver, physician surveys (BOI, preference, trade-offs, satisfaction, adherence etc
Retrospective chart reviews
Qualitative studies
Wearables & digital endpoints
Longitudinal studies

Who We Collaborate With

We partner with biopharmaceutical innovators, emergency departments, infectious disease centers, respiratory specialists, public health organizations, vaccine manufacturers, patient advocacy groups, and healthcare commissioners to advance acute viral infection research and improve outcomes for patients globally.

Let’s Explore Together

Schedule a Consultation – Connect with our infectious disease specialists to discuss how our real-world evidence supports your acute viral infection initiatives.
Discover More – Want to learn about our specialist networks, global footprint, condition expertise, or prevention-focused approach for LRTD, RSV, COVID-19, and influenza? Contact us for detailed insights.

Let’s collaborate to generate evidence that drives innovation and better outcomes for Respiratory Infections.

Contact us today using the form below.

Chronic Viral Infections DSPs

Conferences Attending